The boxed warning is the most serious warning FDA can give, it doesn't apply to 90% of approved FDA drugs so don't act like its nothing.
Side effects is the top consideration for doctor prescribing habit if you look at the market research, there is a reason Travere runs a risk assessment before its prescribed.
Only few (low single digit) incident needs to happen before this goes down the pecking order of doctors. For a doctor, if the drug doesn't work is fine, but if the patient suffers side effects, he loses patients trust. Look at what happened to Beovu, a far more efficacious drug vs Eylea but as soon as patients getting serious side effects, the company struggled to sell its benefits.
Coming to Dimerix side effects, its all relative. So far all studies including the Covid one shows there is no meaningful side effects, sure no one knows what comes out of P3 trial, but likelihood of it showing any adverse effect is low.
Now comes to selling, if Dimerix gets approval for FSGS, there will be a line of companies willing to partner to sell it, don't worry. And the first mover advantage of Travere is blown out of proportion by someone like you, the pond is big enough for multiple fishes even if Dimerix needs to complete full trial, don't you worry.
Good luck to all holers.
DXB Price at posting:
48.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)